Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of its patent application for innovative combinations of Ketamine and N-Acylethanolamines. This is a result of their ongoing collaboration with SciSparc (Nasdaq: SPRC). The companies are researching combination therapies integrating SciSparc's Palmitoylethanolamide (PEA) with Clearmind's psychedelic molecule MEAI, targeting addictions, weight loss, and mental health disorders.
To date, thirteen patents related to this collaboration have been filed globally. The goal is to develop treatments that maintain effectiveness while reducing doses and minimizing side effects. This approach could potentially address concerns associated with FDA-approved ketamine treatments, which require strict usage guidelines and close supervision due to potential side effects and abuse risks.
Clearmind Medicine Inc. (Nasdaq: CMND) ha annunciato la pubblicazione della sua domanda di brevetto per innovative combinazioni di Ketamina e N-Acilethanolamine. Questo è il risultato della loro continua collaborazione con SciSparc (Nasdaq: SPRC). Le aziende stanno ricercando terapie combinate che integrano il Palmitoiletanolamide (PEA) di SciSparc con la molecola psichedelica MEAI di Clearmind, mirando a dipendenze, perdita di peso e disturbi della salute mentale.
Fino ad oggi, sono stati depositati globalmente tredici brevetti relativi a questa collaborazione. L'obiettivo è sviluppare trattamenti che mantengano l'efficacia riducendo le dosi e minimizzando gli effetti collaterali. Questo approccio potrebbe affrontare preoccupazioni associate ai trattamenti a base di ketamina approvati dalla FDA, che richiedono linee guida rigorose e supervisione ravvicinata a causa dei potenziali effetti collaterali e dei rischi di abuso.
Clearmind Medicine Inc. (Nasdaq: CMND) ha anunciado la publicación de su solicitud de patente para combinaciones innovadoras de Ketamina y N-Acilethanolaminas. Esto es el resultado de su colaboración continua con SciSparc (Nasdaq: SPRC). Las empresas están investigando terapias combinadas que integran el Palmitoiletanolamida (PEA) de SciSparc con la molécula psicodélica MEAI de Clearmind, enfocándose en adicciones, pérdida de peso y trastornos de salud mental.
Hasta la fecha, se han presentado trece patentes relacionadas con esta colaboración a nivel mundial. El objetivo es desarrollar tratamientos que mantengan la efectividad mientras reducen las dosis y minimizan los efectos secundarios. Este enfoque podría abordar las preocupaciones asociadas con los tratamientos de ketamina aprobados por la FDA, que requieren pautas de uso estrictas y supervisión cercana debido a los potenciales efectos secundarios y riesgos de abuso.
Clearmind Medicine Inc. (Nasdaq: CMND)는 혁신적인 케타민과 N-아실에탄올아민의 조합에 대한 특허 신청서를 발표했습니다. 이는 SciSparc (Nasdaq: SPRC)와의 지속적인 협력의 결과입니다. 두 회사는 SciSparc의 팔미토일에탄올아민(PEA)을 Clearmind의 환각 분자 MEAI와 통합한 조합 요법을 연구하고 있으며, 이는 중독, 체중 감소 및 정신 건강 장애를 목표로 하고 있습니다.
현재까지 이 협력과 관련하여 전 세계적으로 13개의 특허가 출원되었습니다. 목표는 효과를 유지하면서도 용량을 줄이고 부작용을 최소화하는 치료법을 개발하는 것입니다. 이러한 접근법은 FDA 승인을 받은 케타민 치료와 관련된 우려를 해소할 수 있는데, 이 치료들은 부작용과 남용 위험 때문에 엄격한 사용 지침과 면밀한 감독이 필요합니다.
Clearmind Medicine Inc. (Nasdaq: CMND) a annoncé la publication de sa demande de brevet pour des combinaisons innovantes de Kétamine et N-Acylethanolamines. Cela découle de leur collaboration continue avec SciSparc (Nasdaq: SPRC). Les deux entreprises étudient des thérapies combinées intégrant le Palmitoiletanolamide (PEA) de SciSparc avec la molécule psychédélique MEAI de Clearmind, en visant les addictions, la perte de poids et les troubles de la santé mentale.
À ce jour, treize brevets liés à cette collaboration ont été déposés dans le monde entier. L'objectif est de développer des traitements efficaces tout en réduisant les doses et en minimisant les effets secondaires. Cette approche pourrait potentiellement aborder les préoccupations associées aux traitements par kéamine approuvés par la FDA, qui nécessitent des directives d'utilisation strictes et une supervision rapprochée en raison des effets secondaires potentiels et des risques d'abus.
Clearmind Medicine Inc. (Nasdaq: CMND) hat die Veröffentlichung seines Patentantrags für innovative Kombinationen von Ketamin und N-Acylethanolaminen angekündigt. Dies ist das Ergebnis ihrer fortlaufenden Zusammenarbeit mit SciSparc (Nasdaq: SPRC). Die Unternehmen erforschen Kombinationstherapien, die das Palmitoylethanolamid (PEA) von SciSparc mit dem psychedelischen Molekül MEAI von Clearmind integrieren, mit dem Ziel, Suchtverhalten, Gewichtsreduktion und psychische Gesundheitsstörungen anzugehen.
Bis heute wurden weltweit dreizehn Patente im Zusammenhang mit dieser Zusammenarbeit angemeldet. Ziel ist es, Behandlungen zu entwickeln, die die Wirksamkeit aufrechterhalten und gleichzeitig die Dosen reduzieren und Nebenwirkungen minimieren. Dieser Ansatz könnte potenzielle Bedenken im Zusammenhang mit von der FDA zugelassenen Ketaminbehandlungen ansprechen, da diese strenge Verwendungsvorschriften und eine enge Überwachung erfordern, um möglichen Nebenwirkungen und Missbrauchsrisiken zu begegnen.
- Publication of patent application for innovative Ketamine and N-Acylethanolamines combinations
- Ongoing collaboration with SciSparc for researching combination therapies
- Thirteen patents filed globally related to the collaboration
- Potential to reduce treatment doses while maintaining effectiveness and minimizing side effects
- None.
The publication of Clearmind Medicine's patent application for ketamine-based combination treatments marks a significant development in psychedelic therapeutics. This innovation aims to address the limitations of current ketamine treatments, which require strict supervision due to potential side effects and abuse risks.
The collaboration with SciSparc, focusing on combining Palmitoylethanolamide (PEA) with psychedelic molecules, could potentially revolutionize treatment approaches for addictions, obesity and mental health disorders. The goal of reducing treatment doses while maintaining efficacy and minimizing side effects is particularly promising for improving patient outcomes and expanding treatment accessibility.
However, investors should note that this is still in the early stages of development. The path from patent application to FDA approval is long and uncertain, requiring extensive clinical trials to prove safety and efficacy. While the potential market for improved psychedelic-based treatments is substantial, it's important to monitor the progress of these innovations through the regulatory pipeline.
The combination of ketamine with N-Acylethanolamines represents an intriguing approach to enhancing therapeutic efficacy while potentially mitigating side effects. Ketamine's rapid antidepressant effects are well-documented, but its use is by dissociative side effects and abuse potential. The addition of PEA, known for its anti-inflammatory and neuroprotective properties, could theoretically modulate ketamine's effects on neural circuits.
This synergistic approach might allow for lower doses of ketamine, potentially reducing side effects while maintaining therapeutic benefits. However, it's important to note that the complex pharmacology of psychedelics means that unexpected interactions could occur. Rigorous preclinical and clinical studies will be necessary to establish the safety and efficacy profile of these combinations.
The broader implications of this research extend beyond depression treatment, potentially opening new avenues for addressing addiction and other mental health disorders. This could significantly expand the therapeutic applications of ketamine-based treatments.
Clearmind Medicine's patent application signals a strategic move to strengthen its intellectual property portfolio in the rapidly evolving psychedelic therapeutics market. With 13 patents already filed in collaboration with SciSparc, the company is building a robust barrier to entry for potential competitors.
The focus on combining established compounds like ketamine with novel elements like PEA demonstrates a balanced approach to drug development, potentially reducing regulatory hurdles and development timelines. This strategy could accelerate the path to market and provide a competitive edge in the burgeoning psychedelic therapeutics sector.
However, investors should be aware that the psychedelics market is still nascent and highly speculative. Regulatory challenges, public perception and competition from both pharmaceutical giants and other biotech startups pose significant risks. The company's success will hinge on its ability to navigate these challenges and bring innovative, effective treatments to market.
Vancouver, Canada, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced the publication of its patent application under the international Patent Cooperation Treaty (“PCT”) for innovative combinations of Ketamine and N-Acylethanolamines.
The patent application was filed as a result of the Company's continuous collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialized pharmaceutical company in the clinical trial phase, dedicated to creating treatments for central nervous system disorders.
As part of the collaboration, the two companies are researching combination therapies that integrate SciSparc’s Palmitoylethanolamide (“PEA”) with Clearmind’s innovative psychedelic molecule, 5-methoxy-2-aminoindan (MEAI), aimed at treating addictions, promoting weight loss and addressing mental health disorders. Furthermore, the two companies are jointly exploring new treatments based on different psychedelic molecules and PEA. To date, thirteen patents related to this collaboration have been filled with the U.S. Patent and Trademark Office, as well as several other global jurisdictions.
In 2019, the U.S. Food & Drug Administration (the “FDA”) approved a ketamine derivative as a nasal spray medication for use in adult patients. It is specifically intended to treat depression in patients that have not responded to other treatments and to alleviate depressive symptoms in individuals with major depressive disorder (MDD) who are experiencing suicidal thoughts or exhibiting suicidal behavior.
The approved treatment comes with strict usage guidelines. It must be administered only at certified medical facilities and used alongside an antidepressant medication. After receiving a dose, patients are required to remain at the facility for a two-hour observation period. This allows healthcare providers to monitor for any potentially serious side effects that may occur.
Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, "Through our collaboration with SciSparc, and following extensive research conducted by their team, we have discovered that combining PEA with various different compounds has the potential to reduce treatment doses while maintaining effectiveness and minimizing side effects. Ketamine was approved by the FDA for use under close supervision due to its associated side effects, including the risk of abuse and psychological as well as physical dependence. Our ultimate goal is to provide patients with safe and effective treatments that offer t therapeutic benefits, while minimizing adverse effects. We believe that the collaboration with SciSparc could lead to such solutions.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
About SciSparc Ltd.
SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its ultimate goal to offer patients safe and effective treatments that will allow them to benefit from the therapeutic effects, while minimizing their adverse effects, and its belief that the collaboration with SciSparc may provide such solutions. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the focus of Clearmind Medicine's (CMND) recent patent application?
How many patents has Clearmind Medicine (CMND) filed related to its collaboration with SciSparc?
What are the potential benefits of Clearmind Medicine's (CMND) research on combination therapies?
What health issues is Clearmind Medicine (CMND) targeting with its research?
